Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Loss from operations	$ (5,097,453)	$ (8,246,463)
Adjustments to reconcile net loss to net cash used in operating activities:
Equity-based compensation	1,465,531	2,640,349
Issuance of commitment shares	51,901
Amortization of intangible assets	423	423
Change in value of deferred tax liability	(1,690)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(120,165)	(114,738)
Prepaid research and development		9,931
Accrued expenses	(554,713)	(1,523,685)
Accrued expenses, related party	(145,000)	30,000
Accounts payable	(197,232)	14,749
Net cash used in continuing operating activities – continuing operations	(4,598,398)	(7,189,434)
Net cash used in discontinued operations	(985,856)	(2,245,680)
Net cash used in operating activities	(5,584,254)	(9,435,114)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase consideration received for sale of assets	1,150,000
Net cash provided by investing activities – continuing operations	1,150,000
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from sale of common stock	749,943	9,123,741
Proceeds from warrant exercise	58	1,865
Redemption of fractional shares	(1,661)
Net cash provided by financing activities – continuing operations	748,340	9,125,606
NET DECREASE IN CASH AND CASH EQUIVALENTS	(3,685,914)	(309,508)
CASH AND CASH EQUIVALENTS-BEGINNING OF PERIOD	4,001,794	6,062,173
CASH AND CASH EQUIVALENTS-END OF PERIOD	315,880	5,752,665
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid
Income taxes paid
Equity consideration received for sale of Purnovate	1,727,897
Reimbursement receivable in connection with sale of Purnovate	$ 737,276